Journal article

Continuous Positive Airway Pressure Use for Obstructive Sleep Apnea in Acute, Traumatic Tetraplegia

Marnie Graco, Rachel Schembri, Jacqueline Ross, Sally E Green, Lauren Booker, Peter A Cistulli, Najib T Ayas, David J Berlowitz

Archives of Physical Medicine and Rehabilitation | W B SAUNDERS CO-ELSEVIER INC | Published : 2019


OBJECTIVE: To describe continuous positive airway pressure (CPAP) use for treatment of obstructive sleep apnea (OSA) in acute tetraplegia, including adherence rates and associated factors. DESIGN: Secondary analysis of CPAP data from a multinational randomized controlled trial. SETTING: Inpatient rehabilitation units of 11 spinal cord injury centers. PARTICIPANTS: People with acute, traumatic tetraplegia and OSA (N=79). INTERVENTIONS: Autotitrating CPAP for OSA for 3 months. MAIN OUTCOME MEASURES: Adherence measured as mean daily hours of use. Adherent (yes/no) was defined as an average of at least 4 hours a night throughout the study. Regression analyses determined associations between base..

View full abstract


Awarded by National Health and Medical Research Council (Australia)

Funding Acknowledgements

Supported by the Transport Accident Commission (Victoria, Australia) as an element of the Sleep Health in Quadriplegia research program, and also supported by the National Health and Medical Research Council (Australia; APP1080020) and the Rick Hansen Foundation (Canada). Autosetting CPAP devices were provided as in-kind support by ResMed (San Diego, California). None of the funding agencies contributed to the design of the trial, the collection or analysis of the data, the writing of the manuscript, or the decision to submit the manuscript for publication.P.A.C. has an appointment to an endowed academic chair at the University of Sydney that was established from ResMed funding. He received research support from ResMed, SomnoMed, and Zephyr Sleep Technologies. He is a consultant/adviser to Zephyr Sleep Technologies and ResMed (Narval). He has a pecuniary interest in SomnoMed related to a previous role in R&D (2004). The other authors have nothing to disclose.